GGrantIndex
← Search

CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA

$0M01FY2000RRNIH

Indiana Univ-Purdue Univ At Indianapolis, Indianapolis IN

Investigators

Linked publications & trials

Abstract

This study will be carried out to assess safety, tolerability, and efficacy parameters in HIV-positive patients with oropharyngeal candidiasis (OPC), and also to select a dose or doses prior to initiation of studies in patients with systemic fungal infections. The primary objective: Demonstration of the clinical efficacy of the highest dose of SCH 56592.

View original record on NIH RePORTER →